Literature DB >> 28956736

18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer.

Kelley Salem1, Manoj Kumar1, Ginny L Powers1, Justin J Jeffery1, Yongjun Yan1, Aparna M Mahajan1, Amy M Fowler1.   

Abstract

Purpose To determine the binding specificity of 18F-16α-17β-fluoroestradiol (FES) in estrogen receptor (ER) α-positive breast cancer cells and tumor xenografts. Materials and Methods Protocols were approved by the office of biologic safety and institutional animal care and use committee. By using ER-negative MDA-MB-231 breast cancer cells, clonal lines were created that expressed either wild-type (WT; 231 WT ER) or G521R mutant ERα (231 G521R ER), which is defective in estradiol binding. ERα protein levels, subcellular localization, and transcriptional function were confirmed. FES binding was measured by using an in vitro cell uptake assay. In vivo FES uptake was measured in tumor xenografts by using small-animal positron emission tomographic/computed tomographic imaging of 24 mice (17 WT ER tumors, nine mutant G521R ER tumors, eight MDA-MB-231 tumors, and four MCF-7 ER-positive tumors). Statistical significance was determined by using Mann-Whitney (Wilcoxon rank sum) test. Results ERα transcriptional function was abolished in the mutated 231 G521R ER cells despite appropriate receptor protein expression and nuclear localization. In vitro FES binding in the 231 G521R ER cells was reduced to that observed in the parental cells. Similarly, there was no significant FES uptake in the 231 G521R ER xenografts (percent injected dose [ID] per gram, 0.49 ± 0.042), which was similar to the negative control MDA-MB-231 xenografts (percent ID per gram, 0.42 ± 0.051; P = .20) and nonspecific muscle uptake (percent ID per gram, 0.41 ± 0.0095; P = .06). Conclusion This study showed that FES retention in ER-positive breast cancer is strictly dependent on an intact receptor ligand-binding pocket and that FES binds to ERα with high specificity. These results support the utility of FES imaging for assessing tumor heterogeneity by localizing immunohistochemically ER-positive metastases that lack receptor-binding functionality. © RSNA, 2017 Online supplemental material is available for this article.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28956736      PMCID: PMC5882239          DOI: 10.1148/radiol.2017162956

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  34 in total

1.  Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.

Authors:  Hannah M Linden; Brenda F Kurland; Lanell M Peterson; Erin K Schubert; Julie R Gralow; Jennifer M Specht; Georgiana K Ellis; Thomas J Lawton; Robert B Livingston; Philip H Petra; Jeanne M Link; Kenneth A Krohn; David A Mankoff
Journal:  Clin Cancer Res       Date:  2011-07-12       Impact factor: 12.531

2.  PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.

Authors:  Michel van Kruchten; Andor W J M Glaudemans; Erik F J de Vries; Regina G H Beets-Tan; Carolien P Schröder; Rudi A Dierckx; Elisabeth G E de Vries; Geke A P Hospers
Journal:  J Nucl Med       Date:  2012-01-12       Impact factor: 10.057

3.  Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation.

Authors:  E T Alarid; N Bakopoulos; N Solodin
Journal:  Mol Endocrinol       Date:  1999-09

4.  Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.

Authors:  Pedram Heidari; Francis Deng; Shadi A Esfahani; Alicia K Leece; Timothy M Shoup; Neil Vasdev; Umar Mahmood
Journal:  Clin Cancer Res       Date:  2015-01-21       Impact factor: 12.531

5.  Breast cancer models to study the expression of estrogen receptors with small animal PET imaging.

Authors:  Antonio Aliaga; Jacques A Rousseau; René Ouellette; Jules Cadorette; Johan E van Lier; Roger Lecomte; Francois Bénard
Journal:  Nucl Med Biol       Date:  2004-08       Impact factor: 2.408

6.  Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.

Authors:  Lanell M Peterson; David A Mankoff; Thomas Lawton; Kevin Yagle; Erin K Schubert; Svetlana Stekhova; Allen Gown; Jeanne M Link; Timothy Tewson; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2008-02-20       Impact factor: 10.057

Review 7.  Recommendations and Technical Aspects of 16α-[18F]Fluoro-17β-Estradiol PET to Image the Estrogen Receptor In Vivo: The Groningen Experience.

Authors:  Clasina M Venema; Giulia Apollonio; Geke A P Hospers; Carolina P Schröder; Rudi A J O Dierckx; Erik F J de Vries; Andor W J M Glaudemans
Journal:  Clin Nucl Med       Date:  2016-11       Impact factor: 7.794

8.  [18F]Fluorinated estradiol derivatives for oestrogen receptor imaging: impact of substituents, formulation and specific activity on the biodistribution in breast tumour-bearing mice.

Authors:  François Bénard; Naseem Ahmed; Jean-Mathieu Beauregard; Jacques Rousseau; Antonio Aliaga; Céléna Dubuc; Etienne Croteau; Johan E van Lier
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-13       Impact factor: 9.236

9.  Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.

Authors:  Mary L Gemignani; Sujata Patil; Venkatraman E Seshan; Michelle Sampson; John L Humm; Jason S Lewis; Edi Brogi; Steven M Larson; Monica Morrow; Neeta Pandit-Taskar
Journal:  J Nucl Med       Date:  2013-08-22       Impact factor: 10.057

10.  Quantitative hormone therapy follow-up in an ER+/ERαKD mouse tumor model using FDG and [11C]-methionine PET imaging.

Authors:  Michel Paquette; Sébastien Tremblay; Francois Bénard; Roger Lecomte
Journal:  EJNMMI Res       Date:  2012-11-09       Impact factor: 3.138

View more
  5 in total

1.  18F-Fluoroestradiol PET Imaging of Activating Estrogen Receptor-α Mutations in Breast Cancer.

Authors:  Manoj Kumar; Kelley Salem; Ciara Michel; Justin J Jeffery; Yongjun Yan; Amy M Fowler
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

2.  Determination of binding affinity of molecular imaging agents for steroid hormone receptors in breast cancer.

Authors:  Kelley Salem; Manoj Kumar; Kyle C Kloepping; Ciara J Michel; Yongjun Yan; Amy M Fowler
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-04-25

Review 3.  Recent Advances in Imaging Steroid Hormone Receptors in Breast Cancer.

Authors:  Manoj Kumar; Kelley Salem; Amye J Tevaarwerk; Roberta M Strigel; Amy M Fowler
Journal:  J Nucl Med       Date:  2019-11-15       Impact factor: 10.057

4.  PET Imaging of Estrogen Receptors Using 18F-Based Radioligands.

Authors:  Manoj Kumar; Kelley Salem; Justin J Jeffery; Amy M Fowler
Journal:  Methods Mol Biol       Date:  2022

5.  Relationship between the expression of oestrogen receptor and progesterone receptor and 18F-FDG uptake in endometrial cancer.

Authors:  Chunhua Wu; Ruohua Chen; Lian Xu; Yumei Chen; Yining Wang; Gan Huang; Jianjun Liu
Journal:  Aging (Albany NY)       Date:  2020-07-08       Impact factor: 5.682

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.